MG Myasthenia gravis Pemphigus
Conditions
Interventions
None listed
Sponsors
Leids Universitair Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: For myasthenia gravis: 1. Males and females aged between 18 years and older at the time of the blood donation. 2. Patient with ocular or generalized AChR MG, MuSK MG or LEMS; and 3. A positive serologic test for AChR antibodies > 0.5 nmol/l or MuSK antibodies >0.1 nmol/l or VGCC antibodies >20 fmol/l. , For Pemphigus: 1. Males and females aged between 18 years and older at the time of the blood donation. 2. Patient with pemphigus subtypes and 3. A positive serologic test for Dsg1 antibodies > 0.5 nmol/l or Dsg3 antibodies >0.1 nmol/l.
Exclusion criteria
Exclusion criteria: For myasthenia gravis and pemphigus: 1. Any confirmed or suspected immunosuppressive or immunodeficient condition not related to the treatment of MG, including human immunodeficiency virus (HIV) infection, or a family history of congenital or hereditary immunodeficiency. 2. History or evidence of administration of immunoglobulins within 1 month prior to the blood withdrawal. 3. The investigator can exclude patients for this trial which are deemed not suitable for any reason.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary Objective: - To isolate PBMC from patients with AChR MG, MuSK MG, LEMS or pemphigus to determine the pathogenic B cell receptor sequences. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary Objective(s): - To generate recombinant antibodies derived from pathogenic auto-antibodies from AChR MG, MuSK MG, LEMS or pemphigus patients. - To determine the phenotype of pathogenic antibody producing B cells. - To correlate disease severity and other patient characteristics with pathogenic antibody producing B cell numbers and B cell receptor sequences. | — |
Countries
Netherlands
Outcome results
None listed